首页> 外文期刊>Chemical biology and drug design >In silico Characterization of an Atypical MAPK Phosphatase of Plasmodium falciparum as a Suitable Target for Drug Discovery
【24h】

In silico Characterization of an Atypical MAPK Phosphatase of Plasmodium falciparum as a Suitable Target for Drug Discovery

机译:恶性疟原虫的非典型MAPK磷酸酶作为药物发现的合适靶标的计算机表征

获取原文
获取原文并翻译 | 示例
           

摘要

Plasmodium falciparum, the causative agent of malaria, contributes to significant morbidity and mortality worldwide. Forward genetic analysis of the blood-stage asexual cycle identified the putative phosphatase from PF3D7_1305500 as an important element of intraerythrocytic development expressed throughout the life cycle. Our preliminary evaluation identified it as an atypical mitogen-activated protein kinase phosphatase. Additional bioinformatic analysis delineated a conserved signature motif and three residues with potential importance to functional activity of the atypical dual-specificity phosphatase domain. A homology model of the dual-specificity phosphatase domain was developed for use in high-throughput in silico screening of the available library of antimalarial compounds from ChEMBL-NTD. Seven compounds from this set with predicted affinity to the active site were tested against in vitro cultures, and three had reduced activity against a PF3D7_1305 500 parasite, suggesting PF3D7_1305500 is a potential target of the selected compounds. Identification of these compounds provides a novel starting point for a structure-based drug discovery strategy that moves us closer toward the discovery of new classes of clinical antimalarial drugs. These data suggest that mitogen-activated protein kinase phosphatases represent a potentially new class of P. falciparum drug target.
机译:疟疾的病原体恶性疟原虫在全球范围内导致大量发病和死亡。对血液阶段无性循环的正向遗传分析确定,PF3D7_1305500的假定磷酸酶是整个生命周期中表达的红细胞内发育的重要元素。我们的初步评估将其鉴定为非典型的促分裂原活化蛋白激酶磷酸酶。其他生物信息学分析描绘了保守的签名基序和三个残基,这些残基对非典型双特异性磷酸酶结构域的功能活性具有潜在的重要性。开发了双特异性磷酸酶结构域的同源性模型,用于高通量计算机筛选来自ChEMBL-NTD的可用抗疟疾化合物文库。测试了该组中七种对活性位点具有预测亲和力的化合物的抗体外培养物,其中三种对PF3D7_1305 500寄生虫的活性降低,表明PF3D7_1305500是所选化合物的潜在目标。这些化合物的鉴定为基于结构的药物发现策略提供了新的起点,这使我们更接近于发现新型的临床抗疟药。这些数据表明,促分裂原活化的蛋白激酶磷酸酶代表了恶性疟原虫药物靶标的潜在新类别。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号